gms | German Medical Science

Figure

Figure 3: Population health benefit fraction lost in SHI due to the SHI-PHI-disparity in access to sumatriptan. Due to the high prevalence of SHI among patients with migraine headaches, nearly 60 percent of the country-wide attainable incremental benefit of triptan therapy was lost.